Investorideas.com newswire, stock news and business news for investors

Tuesday, January 21, 2014

Penny Stock Trading Alert; TSX Biotech Stock: Q&A Interview with CEO of Quest PharmaTech (TSX.V: QPT)

New York NY - Point Roberts WA - January 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues an exclusive interview with Dr. Madi R. Madiyalakan, Ph.D., Chief Executive Officer of Quest PharmaTech Inc. (TSX.V: QPT). Dr. Madiyalakan shares insight into the Company’s pipeline of oncology products. The Company takes a unique approach to cancer treatment that capitalizes on the recent major advances in the understanding of immune physiology and developing proprietary next generation cancer immunotherapy treatments using select antibodies, adjuvants and photosensitizers.

Interview:
Q: Investorideas.com
For readers unfamiliar with your company, can you give a brief introduction on your background in the biotech space and the formation of Quest PharmaTech?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
I have been involved in the Biotech industry for over 27 years, first as a scientist at Biomira Inc (now known as Oncothyreon) and then as a founding executive team member of several biotech companies including, AltaRex Corp., CanBiocin Inc. and SonoLight Pharmaceuticals Corp. My relationship with Quest began when Quest PharmaTech acquired SonoLight Pharmaceuticals in 2001. That acquisition provided a path forward for technology I had invented and championed ([Dr. Madiyalakan holds 10 primary U.S. patents and eight pending patents]). I have been instrumental in raising more than $200 million through private placement and public offerings for those companies. I specialize in advancing novel technologies with great therapeutic potential in areas of unmet medical need.
Quest was started as a research and development company in 1998 and was listed on the TSX Venture Exchange in 1999. I have been CEO of the Company since 2006.
Q: Investorideas.com
Can you briefly describe the current product portfolio and the primary oncology focus for each?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Our technology is focused on the immunotherapy of cancer. We utilize tumor directed monoclonal antibodies to activate the specific immunity; however we recognize that successful therapy requires orchestrated combination with chemotherapy, photodynamic therapy and select additional immune modulators or adjuvants. Our lead product, Oregovomab, which is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. It is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients. Our pipeline also includes proprietary antibodies against other cancer markers, most notably MUC1, PSA and HER2. We expect to advance our MUC1 targeting antibody into the clinic in the coming year. MUC1 expressing cancers include many commonly occurring solid cancers such as breast, pancreatic and lung cancers.
We are also very excited about our new pipeline of therapeutic IgE antibodies, which we recently acquired from Advanced Immune Therapeutics, Inc. and for which we obtained license rights from UCLA and Stanford University. In addition to their immunotherapeutic potential, these molecules also have the potential to act in the tumor micro-environment to augment the effectiveness of chemotherapy. We truly believe that the IgE technology will be a breakthrough for the treatment of cancer.
Q: Investorideas.com
Can you discuss the current status of your flagship product OREGOVOMAB and its applications in immune therapy?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Quest's proprietary approach uses antibodies to modulate and enhance specific immunity to the target tumor antigen and associated tumor. Recent insights into the ability of cytotoxic therapy to enhance immunity, and the development of novel adjuvant approaches, suggests that a simple and artful approach using a combination of components for specific cancer immunotherapy can change the clinical course of cancer. We are using our lead product Oregovomab as an example to demonstrate the proof of concept for the combinatorial immunotherapeutic approach and trying to identify ideal combinations by conducting three different clinical trials. The most advanced of these is an 80 patient phase II clinical trial in advanced ovarian cancer patients that is being conducted in 13 clinical centers in Italy and the U.S. We hope the results from this trial will confirm the findings in an earlier study that shows combining chemotherapy with Oregovomab leads to the generation of specific anti-cancer T-cells and the potential for clinical benefits. We are also conducting another clinical trial in the U.S. using Oregovomab in combination with another chemotherapeutic agent, Gemcitabine, together with radiation therapy for treating pancreatic cancer. The trial will help us to expand the market opportunities for Oregovomab to other CA125 expressing cancers as well as to evaluate immunotherapy in combination with chemo radiotherapy. We are also looking at the addition of an immunoadjuvant, Hiltonol, a TLR3 agonist, which we have licensed from a U.S based company, Oncovir, to further augment the immune response. The completion of these 3 clinical trials will provide us with the roadmap for commercialization of this product. To summarize, Quest's approach has created an opportunity to mobilize immunity, better, more precisely and for less cost than other methods that are in development, and, or, recently approved.
Q: Investorideas.com
Can you give us some background on the key members of your team and the scientific board and the expertise they bring to the company?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Working with me on themanagement team, I have Thomas Woo, Vice President of Product Development since 2002. Thomas honed his drug development skills at Biomira, AltaRex and Cytovax. My CFO, Pierre Vermette, comes with extensive experience gained at the Alberta Securities Commission and has been with the Company since 2003.
On theBoard of Directors, I have Lorne Meikle, our Chairman, Ian McConnan, our Audit Committee Chair and Paul Van Damme, our Corporate Governance Chair.
Mr. Meikle has an extensive background in the life sciences area, Mr. McConnan is a former partner of several public accounting firms, and Mr. Van Damme has acted in the CFO role for a number of public and private companies.
On the Company's Scientific Advisory Board, I have internationally known scientists who occupy important positions in various institutions around the world. Dr. Samuel Abraham, Ph.D., is the Vice President of Research with the British Columbia Cancer Agency. Professor Ki-Jun Hwang is a well respected medicinal chemist at Chonbuk University in South Korea. One of the clinicians, Dr. Ronald Moore, who is developing a unique treatment for prostate cancer at the Cross Cancer Institute in Canada, is also one of our scientific advisory board members. Dr. Moore, along with Dr. Gerald Miller in Australia, provide a strong scientific direction to our photodynamic therapy program.
On the Company's Clinical Advisory Board (CAB), I have Dr. Christopher Nicodemus, a clinical expert in tumor immunology and drug development who has been championing the combinatorial immunotherapeutic approach supported by numerous publications and patents. He relies on the advice of his fellow CAB members, key opinion leaders such as Professor William McGuire in the U.S, Professor Ignace Vergote in Belgium and Dr. Thomas Ehlen in Canada.
All members of the CAB have a keen interest in innovative improvements in the area of ovarian cancer and see a great opportunity to advance the previous learning with Oregovomab in the context of combination therapies that will better access the immune response and limit immune suppression that has impeded earlier efforts to vaccinate against cancer.
Q: Investorideas.com
Can you share with readers the significance of some of your key relationships including Stanford University and UCLA?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Significance of Key Relationships:
We are very pleased to be licensing IgE technologies developed by the distinguished scientists from these prestigious institutions. In addition, we are also working closely with the Eppley Cancer Institute at the University of Nebraska to develop animal models and complete pre-clinical testing of potential drug candidates.
Q: Investorideas.com
With all biotech companies, funding is a key factor to success; last November you announced a $1million placement for Quest PharmaTech. C an you explain the significance of this round of financing and where this takes you to?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
We wanted to strengthen our relationship with our long term investment partner, AD Biotech Co., Ltd. AD Biotech has committed $12 Million to fund our ongoing clinical programs during the next two years. We were pleased with their confidence in Quest as demonstrated by their investment of $1 Million at a premium share price.
Q: Investorideas.com
In closing what are some of the key milestones for 2014 for Quest PharmaTech?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Some of the key 2014 milestones we hope to achieve in the coming year include completing patient enrollment of the Oregovomab clinical trial and obtaining preliminary data for the Oregovomab clinical trial in Italy and US; initiating a clinical study combining Oregovomab with immuno-adjuvants; expanding the Company's opportunities for revenue generation through product sales of some evidence based over-the-counter nutraceutical and cosmetic products licensed from our joint venture partner; generating critical additional data demonstrating the therapeutic potential of our proprietary IgE portfolio; and, pursuing out-licensing arrangements as a source of additional revenue and validation for our technologies.
About Quest PharmaTech Inc.:
Quest PharmaTech Inc. (Quest) is a publicly traded (TSX Venture), Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy or photodynamic therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone. http://www.questpharmatech.com/
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy and Latin American stocks.
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: QPT.V, a public company, has engaged Investorideas.com for public relations services for four thousand a month retainer fee.
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Monday, December 16, 2013

Penny Stock Trading Alert; Solar Stock XsunX (OTCQB: XSNX) Announces Sales and Building Momentum Into 2014

ALISO VIEJO, CA - December 16, 2013 (Investorideas.com renewable energy newswire) XsunX, Inc. (OTCQB: XSNX), a renewable energy technology, systems, and services company, today announced adding 50kW in signed projects to its growing PV system development and installation services pipeline. The Company is focused on signing more solar contracts before year end.

"We are very excited about the rapid progress we have been making, and announcing 50kW in new projects just adds to our momentum," stated XsunX CEO, Tom Djokovich.
The Company has been working to develop solar projects for a diverse set of clients ranging from professional service companies, to ranch land, to large scale industrial reclamation. The Company has been working directly with new business clients to document the financial benefits available from solar for their businesses.
To help expand and accelerate the growth of the Company's PV system development and installation services business, XsunX has launched a media marketing campaign which targets major Southern California communities ranging from Ventura to the Inland Empire, LA, Orange County and portions of San Diego county. This market represents one of the largest commercial PV system markets in the country and thousands of potential commercial PV system clients for XsunX.
"The message and the reality is that solar has become far more than just a way to cut utility costs. A commercial PV system can provide clients with a 100% cash value return on their investment in as little as three years, and well in excess of a 1000% return on every dollar invested over the life of the system," concluded Mr. Djokovich.
About XsunX
XsunX focuses on providing solar energy solutions that provide the greatest bottom-line financial benefits. The Company's background and experience spans virtually all aspects of solar including technology assessment, design, and development. We have a deep passion for solar and have worked to pioneer new technologies and solar business solutions focused at making solar an affordable energy option. For more information, please visit the Company's website at www.xsunx.com.
Safe Harbor Statement
Matters discussed in this release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein, are included in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact:
Tom Djokovich
President and CEO
949-330-8060
info@xsunx.com
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by XSNX for news distribution averaging 1500 per month. http://www.investorideas.com/About/Disclaimer.asp

Penny Stock Trading Alert; Social Media Stock Alert: UMeWorld (OTCQB:UMEWF) Announces Recent Business Developments

HONG KONG - December 16, 2013 (Investorideas.com newswire) UMeWorld Limited (OTCQB: UMEWF) an emerging digital media company based in China, today announces its recent business developments as of December 16, 2013 and the outlook for the 1st quarter of 2014.

Press Releases Issued During the Period:
  • Dec 3, 2013 - UMeWorld to Monetize its UMeLook Video Platform.
  • Nov 26, 2013 - UMeWorld Releases UMFun™ Final Version, Praised by China State Media.
  • Nov 8, 2013 - UMeWorld’s Video Platform Surpasses 7.2 Million Unique Visitors.
  • Oct 14, 2013 - UMeWorld Launches Revamped Brand Channels on UMeLook.com.
  • Oct 1, 2013 - UMeWorld Launches UMFun™.
  • Sep 18, 2013 - UMeWorld Provides Corporate Update.
Recent Corporate Development During the Period:
  • UMeWorld presents at SeeThruEquity Microcap Investor Conference in New York City.
  • UMeWorld initiates two online Investor Relation programs.
  • UMeWorld completes internal corporate development review and held discussions with two investment banks for Investment Banking and Advisory services.
  • UMeWorld identifies an acquisition target and engages in negotiations.
Upcoming Development in the 1st Quarter of 2014:
  • UMeLook to introduce Basic and Gold paid membership program to its Brand Channel.
  • UMeLook to release an App optimized for Android tablets and Smartphones.
  • UMFun to open an online store, where registered users will be able to use their U Coins (a virtual currency earned in UMeFun.com) to purchase gifts or services.
  • UMFun to introduce an off-line Affiliate Program in which registered users will be rewarded by U Coins and Tools for introducing other users to UMFun.
About UMeWorld
UMeWorld's mission is to facilitate the interaction between people -- "You" and "Me," through its digital platform. Currently, UMeWorld operates UMeLook (www.umelook.com), an online video platform focused on bringing foreign video content to China. UMeLook is deployed through a sophisticated CDN (Content Delivery Network) with broad coverage throughout mainland China, Hong Kong & Taiwan. UMeLook plans to be a source of foreign video content for the Chinese viewer across any Internet-enabled device in China. UMeWorld intends to focus its future operations on digital media and the digital education market.
Forward Looking Statement
This release may contain projections and other forward-looking statements that involve risks and uncertainties. Forward-looking statements are projections reflecting management's judgment and assumptions based on currently available information and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Future performance cannot be assured. Readers are referred to the documents filed by UMeWorld with the Securities and Exchange Commission (SEC), specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements.
For more information, please contact:
UMeWorld Limited
Michael Lee, 852-2824-8716
Investor Relations
info@UMeWorld.com
Published at Investorideas.com – Big Ideas for Global Investors
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: UMEWF compensates Investorideas.com for news publication and syndication : one thousand per month
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Wednesday, December 11, 2013

Penny Stock Trading Alert; Biometric Stock Alert: NXT-ID, Inc. (OTCQB: NXTD) Upcoming Release of Wocket(TM) Taps Into Ramping Demand for Digital Wallets and Currencies

BOSTON, MA - December 11, 2013 (Investorideas.com Newswire) SoundView Technology Group: New research note points to recent industry developments as important drivers to adoption of the upcoming NXT-ID (OTCQB: NXTD) Wocket.

Over 7 million consumers have watched a marketing video for a new digital wallet with a very limited feature set. Consumer interest in this product area is high and accelerating.
The commercial development of new digital currencies like Bitcoin has continued despite extreme price volatility. Industry leaders from companies like PayPal have acknowledged the value and viability of the new currency. At the same time mainstream venture capital firms like Andreesen Horowitz have stepped up their efforts to find "major bets" to make in this new market.
These industry developments increase our confidence and enthusiasm for the NXT-ID (NXTD) Wocket™ both as a digital wallet and a potential secure storage option for Bitcoins. As we outline in our note, the Wocket has a much more robust design in terms of security and usability.
We see the following as key advantages for the NXT-ID Wocket:
Security: Using a secure chip the Wocket can store 100s of cards and digital records. Authentication is multi-factor and includes biometrics. Cards go into the Wocket directly without involving unsecure intermediate steps.
Usability: The Wocket includes an ultra-lower power touchscreen display in addition to the dynamic magnetic stripe as both a UI and QR-code mechanism. A combination of power management, in-wallet charging and standard battery means that consumers won't have to fear a "dead wallet."
Flexibility: Rather than being tied to a phone or platform the Wocket can be paired with any device either locally or in the cloud when secure protocols are available. This dynamic pairing is a key feature of the NXT-ID approach and is a powerful and highly differentiated aspect of their technology.
NXT-ID is an early stage technology company going after a large market. Based on initial traction and a conservative intrinsic valuation (IV) model show a fair value of $11/share we see the company continuing to benefit from intensive investor attention to this space.
Our full report is available for download here: http://s3.amazonaws.com/Published_Research/NXT-ID_NXTD_NOTE_DEC_2013.pdf
About SoundView Technology Group
We are an independent advisory and research firm specializing in emerging technologies as they reach commercialization. Our proprietary research and modeling work provides valuable information for company management teams and investors in these emerging opportunities. We regularly publish our findings across a variety of channels including all the major retail and institutional information outlets. SoundView is based in Boston, Massachusetts with locations in New York and Connecticut.
Disclosures
SoundView analysts do not receive compensation for their research opinions, any specific views or conclusions. They are tasked to provide fact-based research with sound analysis. SoundView does not provide investment advice or make "buy/sell/hold" recommendations. Nor do we provide investment banking or brokerage services. We act as a publisher of our own research work and are responsible for all content which is correct to the best of our abilities but by no means should it be relied upon without further validation and confirmation. SoundView provides paid advisory services NXT-ID on their business plans, technology description and investor positioning
Contact:
Kris Tuttle
Director of Research
SoundView Technology Group
617-828-6462
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013 :Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous services
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Monday, December 9, 2013

Peny Stock Trading Alert: The Wocket and COIN Set the Stage for Changing Your Wallet as You Know It

Point Roberts, WA, NEW YORK, NY - December 9, 2013 (Investorideas.com Newswire) Investorideas.com, an investor news and research portal specializing in leading sectors including biometrics and mobile technology issues an exclusive interview with Mr. Gino Pereira, Chief Executive Officer of NXT-ID, Inc (OTCQB: NXTD) and Mr. Kanishk Parashar, CEO of Coin. The CEOs discuss their innovative payment technologies coming to market in 2014.

Each company has a different approach, technology base, product benefits and security features but both have the same goal; to make it simpler, easier and more secure for consumers to manage their credit cards.
As the two companies prepare for their roll-out in 2014, Investorideas interviews both CEOs to give consumers insight as to what will differentiate the products to the end user.
NXT-ID, Inc’s, The Wocket™ contains a single secure smart card that can hold up to 100 cards and is designed to replace all the cards in your wallet. The Wocket™ works anywhere that credit cards are accepted and can only be used with your biometric or touch screen authentication. The Wocket™ is scheduled to come to market in the first quarter of 2014.
COIN, a company that puts eight credit cards in one COIN is taking pre- orders from consumers for delivery in the summer in 2014. Management believes believe Coin is a substantial improvement on how consumers interact with, and use cards that have a magnetic stripe.
NXT-ID, Inc Interview:
Q: Investorideas.com
What is the idea behind the wocket™?
A: Gino Pereira, Chief Executive Officer of NXT-ID, Inc
The wocket™ is our interpretation of everything a modern wallet should be. It has a single reprogrammable credit card within the wocket to allow secure payments to be made in a traditional manner but the wocket has other functionality too and will be able to display identification as well as hold cash just like a traditional wallet.
Q: Investorideas.com
What is the battery life of the smart card in the wocket?
A: Gino Pereira, Chief Executive Officer of NXT-ID, Inc
The smart card in the wocket is automatically recharged when it is in the wocket so it will never run out of juice! The wocket uses two CR batteries that need to be replaced every 2 to 4 years depending on frequency of use but they are inexpensive and widely available.
Q: Investorideas.com
Does the phone need to be near for the wocket to work?
A: Gino Pereira, Chief Executive Officer of NXT-ID, Inc
No. The wocket does not depend on a phone to work. In fact no confidential information in the wocket is ever passed through a phone or the internet. It is an important security feature.
Q: Investorideas.com
What security features does the wocket have?
A: Gino Pereira, Chief Executive Officer of NXT-ID, Inc
In order to access the wocket for use, the user must authenticate themselves through the use of a multi-factor voice biometric algorithm or through a unique identifier on the touch screen. As we have previously stated, no confidential information in the wocket is ever passed through a phone. The confidential card information is loaded directly on to the wocket through a scanner that has an input directly into the wocket. In addition after the card is used, the wocket zeroizes the magnetic strip meaning no information is retained on the card. If the card is lost there is no useful information on it. In fact purchasers can subscribe to an insurance plan with us so that if their card is lost we will replace it overnight and they can continue life as normal within 24 hrs.
Q: Investorideas.com
What features does the wocket offer other than making credit card payments?
A: Gino Pereira, Chief Executive Officer of NXT-ID, Inc
Any card with a magnetic stripe can be loaded on the wocket so debit cards, gas cards, supermarket cards and other loyalty cards can all be used. The wocket can also display barcodes and identity cards. The fact that the wocket is a smart wallet also means that future editions will be able to make touchless payments, often known as “touch and go”, and NFC capability means that you could even use it at to make EZ-pass payments while you are driving. Of course you will also be able to hold cash in your wocket as well.
COIN Interview:
Q: Investorideas.com
I had read that the battery life of COIN is 2 years; is that correct? And if so what kind of usage is that based on in testing?
A: Kanishk Parashar, CEO of Coin
COIN’s battery life is 2 years under normal usage. Normal usage is 10 swipes per day.
Q: Investorideas.com
What happens if the phone battery dies? does it still work?
A: Kanishk Parashar, CEO of Coin
Coin uses the concept of a leash, when the phone battery dies, the leash breaks and Coin locks down and disables itself. Once this happens, users can manually unlock Coin using a single button passcode (similar to a morse code) and continue to use their Coin without their phone.
Q: Investorideas.com
How do they get the credit info onto the phone app? How is it downloaded?
A: Kanishk Parashar, CEO of Coin
Credit card info is downloaded to your phone app by first taking a picture of the front and back of your card, answering personal security questions and finally through a card reader dongle attached to your phone.
Q: Investorideas.com
Have you tested the magnetic stripe with all kinds of payment cards? And can you say which ones?
A: Kanishk Parashar, CEO of Coin
We have proven and tested the magnetic stripe with all kinds of payment cards such as Visa, MasterCard, and AMEX just to name a few, as well as other magnetic striped cards like loyalty cards, gift cards, and membership cards.
Q: Investorideas.com
Does the phone need to be near for COIN to work?
A: Kanishk Parashar, CEO of Coin
( as per question 2) Coin uses the concept of a leash, when the phone battery dies, the leash breaks and Coin locks down and disables itself. Once this happens, users can manually unlock Coin using a single button passcode (similar to a morse code) and continue to use their Coin without their phone.
Q: Investorideas.com What stops someone that gets a hold of your COIN, from accessing all 8 cards you may have downloaded? For example what happens if it falls in the hands of either a customer service person or if you loose it or someone steals it?
A: Kanishk Parashar, CEO of Coin
When you give your COIN to a customer service person or waiter, you can lock the card to avoid unwanted swipes from occurring. Additionally COIN will keep track of the number of times it is swiped and will alert you when actions are suspicious. When your COIN is lost or stolen, it will be disabled and inoperable as soon as it breaks connectivity with your mobile phone and will not function until it is manually enabled or reconnected to your phone.
About NXT- ID Inc. - (OTCQB: NXTD) Mobile Security for a Mobile World
NXT-ID, Inc.'s innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID’ wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/, http://thewocket.com/
About COIN
Hold all your cards in one Coin.
https://onlycoin.com/about/
About www.InvestorIdeas.com : Big Ideas for global investors, InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus Investorideas is long shares in the company.
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Contact Information
Investorideas.com

800-665-0411
or 212-822-8842 Sources: Investorideas.com, COIN, NXT- ID Inc

Wednesday, December 4, 2013

Penny Stock Trading Alert; Biopharma Stock News Alert: SUNSHINE BIOPHARMA (OTCQB: SBFM) EXPANSION AND FINANCING OPPORTUNITIES FOR Adva-27a CANCER DRUG CANDIDATE: Company to RE-DOMICILE IN CANADA

Montreal, Quebec, Canada - December 4, 2013 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is re-domiciling the Company in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations. To this end, The Company filed a Schedule 14-C Information Statement on September 16, 2013 and an S-4 Registration Statement on October 23, 2013.

"We are very pleased that the re-domiciling process is going smoothly", said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Re-domiciling the Company in Canada will give us access to a more favorable fiscal environment and provide with greater flexibility to execute our business plan. This will better position our Company for expansion and allow us to capitalize on growth opportunities as our Adva-27a drug candidate enters the clinic."
About Adva-27a
Adva-27a is Sunshine Biopharma’s lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Tuesday, December 3, 2013

Penny Stock Trading Alert; Biometric Stock Alert: NXT-ID, Inc. (OTCQB: NXTD) Announces Product Features for Next Generation Electronic Wallet, "The Wocket(TM)"

SHELTON, CT - December 3, 2013 (Investorideas.com Newswire) NXT-ID Inc. (OTCQB: NXTD), a biometrics company focused on the growing mobile commerce market, today announced features of its next generation wallet, The Wocket™, scheduled for launch for the first quarter of 2014.

The Wocket™ is designed to replace all the cards in your wallet with a single, secure smart card. The Wocket™ works anywhere that credit cards are accepted and can only be used with your biometric or touch screen authentication.
The world of wallets is about to change with new and exciting technologies making payments easier than ever. However, most credit card holders are understandably reluctant to use their smartphone for transactions -- this is due to a variety of reasons including:
  • Limited battery life
  • Dependency on wireless network coverage
  • Well publicized security threats
Rather than depending on a smartphone for transactions, NXT-ID has developed a truly next generation electronic wallet.
This unique technology takes a very different approach: Instead of replacing the wallet, NXT-ID is improving it. The Company's innovative Wocket™ replaces all the cards in your wallet with one single re-programmable card that supports most payment methods currently available at a Point-of-Sale (POS) at retailers around the world (magnetic stripe, NFC and barcode)... all within a secure biometric vault.
Access your Wocket™ with security on the touch screen or through voice authentication biometrics and select which card you wish to use; now use that card to substitute any card in your wallet. What's more, no personal information is retained on the magnetic stripe so the risk of fraud is greatly reduced.
Now you can bring the wallet you know and love into the future with the Wocket™ and have advanced secure electronic wallet technology from NXT-ID.
Availability:
NXT-ID will be launching the Wocket in the first quarter of 2014.
Product Features and Benefits
  • Card reader plugs in directly to Wocket
  • Card information is erased after every transaction
  • Does not require phone
  • Number of cards- Approximately 100 cards, records, coupons, etc.
  • Authentication - Multi-factor (user configurable) Dynamic Pairing of voice and word
  • User Interface: Display and or Voice
  • Payment methods: Dynamic Mag Stripe, QR Code
  • Battery: Replaceable CR batteries in the Wocket.
  • Life: Unlimited with in-wallet charging of dynamic card.
Stay tuned for further announcements at the company website and at http://thewocket.com/
About NXT-ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID's wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013 :Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous services
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.